

2012 Investor Conference

June 1, 2012 · New York City



Chris O'Connell

EXECUTIVE VICE PRESIDENT & RESTORATIVE THERAPIES GROUP PRESIDENT MEDTRONIC INC.



FORWARD-LOOKING STATEMENT


Some of the statements contained in today's program may be considered forwardlooking statements which provide current expectations or forecasts of future events. These forward-looking statements generally relate to market and revenue growth, financial results, use of free cash flow, product development, and sales efforts. They are based on current assumptions and/or expectations that involve a number of uncertainties or risks. These uncertainties and risks include, but are not limited to, those outlined in Medtronic's Annual Report on Form 10-K for the year ended April 29, 2011, and other documents filed from time to time with the U.S. Securities and Exchange Commission (SEC). Investors are advised to review any further disclosures which may be made in such reports filed periodically with the SEC. Forward-looking statements are made as of today's date, and the Company undertakes no duty to update them. In addition, non-GAAP to GAAP reconciliations are posted on our website.

🕀 Medtronic

RTG WILL BE A SIGNIFICANT CONTRIBUTOR TO IMPROVING MEDTRONIC GROWTH RTG WELL POSITIONED IN GROWTH MARKETS

Spine has a clear improvement path in the dynamic U.S. market, and is winning internationally


Surgical Technologies, Neuromodulation, and Diabetes all showing strong execution and robust product pipeline



Globalization driving current performance and investment in all four RTG businesses

🕀 Medtronic





LEVERAGING COMPETITIVE ADVANTAGES TO RETURN TO GROWTH OUR GAME PLAN TO WIN IN SPINE **DEEP DIVE ON U.S.:** Differentiated technology Innovation Core Spine Procedural innovation 1. 2. BKP Smart Surgery 3. INFUSE® Local R&D / Manufacturing Globalization Reverse innovation Sales force expansion Resource Aggressive cost management Reallocation Create incremental R&D spend · Shift investment to growth markets 🕀 Medtronic

SEVERAL FACTORS HAVE AFFECTED THE MARKET U.S. CORE MARKET CHALLENGED BUT STABILIZING



U.S. Core Spine Market Dynamics

	<u>Q4 FY10</u>	<u>Q4 FY12</u>
Procedures	+6%	+1%
Price	-1%	-5%
Mix	+2%	+3%


U.S. Core Spine Market Challenges


- Economic slowdown, including unemployment
- Price pressure in segments with limited differentiation
- Perceived over-utilization in certain segments
- Growth in "unaddressable" segments (e.g. PODs)

* U.S. Core Spine is equal to U.S. Core Spinal minus BKP plus Other Biologics.


NEAR-TERM DRIVERS TO IMPROVE SPINE PERFORMANCE MEDTRONIC U.S. CORE SPINE IS STABILIZING









MOVING FROM PRODUCTS TO PROCEDURES TO INCREASE COMPETITIVE ADVANTAGE PROCEDURAL INNOVATION: MAST[®] MIDLFTM





NEW PRODUCT DIFFERENTIATION IMPROVING GROWTH STABILIZATION IN U.S. KYPHOPLASTY



Past Headwinds

- NEJM article questioned surgical intervention; BKP drawn down with vertebroplasty
- Payer pressure accelerated (e.g., Noridian)
- Price pressure with new competitors

Near-Term Drivers

- Recent evidence: CAFÉ, FREE, mortality data, life expectancy / cost effectiveness data
- Kyphon Xpander[®] II, KIS, Xpede[™] and InflateFX[™] increasing competitive differentiation

STAYING PATIENT AND FOCUSED DURING TURBULENT TIME FOR INFUSE ADDRESSING U.S. INFUSE® CONCERNS



- Sales stabilizing after two sharp falls
- Remain highly confident in safety and efficacy of BMP-2 as a revolutionary bone graft product
- DOJ has dropped off-label investigation
- Yale study: unprecedented transparency
 - Providing all data, published and unpublished
 - Two independent systematic reviews of patient-level data
 - New standard for clinical data integrity
- Continue to invest in BMP-2 technology
 - INDUCTOS launch internationally
 - New INFUSE carrier and indication development

15

MARKETS OUTSIDE THE UNITED STATES ARE VERY LARGE AND UNDERPENETRATED

FY12

\$ Millions – Constant Fx 1,000 Emerging Markets Developed Markets 750 - 25% CAGR

3% CAGR

FY11

FY10

500

250

0

🖗 Medtronic


FY09

MDT Spine International Revenue

Major International Strategies

- 1. Localized R&D and manufacturing
 - Europe, China, Japan, India
 - 65% increase in local R&D in last 3 years
- 2. Building on Weigao JV success
 - Already driving reverse innovation
- 3. 33% growth in Emerging Market FY12 sales & marketing investment

16




COMPACT CORNERSTONE OFFERS GLIMPSE OF FUTURE FIRST EXAMPLE OF REVERSE INNOVATION




COMPACT CORNERSTONE® IMPROVED | LEANER | LESS COSTLY

- Based on original Cornerstone implant
- New configuration developed in Europe
 - 60% reduction in instrument cost
 - 30% reduction in implant cost
 - Easier handling & better anatomical fit
 - Leaner instrument set
- Manufactured in China
- Will deploy aggressively in developed markets as demand builds



PUSHING CHANGE AND ATTACKING COSTS TO FUND INVESTMENTS DISCIPLINED FOCUS ON COST STRUCTURE



GAINING EFFICIENCIES

- Eliminated 9% of US non-production positions in FY12
- Integrated US sales forces for Biologics and Core
- Consolidated Sunnyvale while preserving R&D center
- Shifted instrument production to low-cost source

PRIORITIZING GROWTH INVESTMENTS

- Rebalancing R&D investment in FY13
- Expanding product development into Europe and Japan
- Launching new INFUSE[®] trials to supplement Yale work

EXCITEMENT AND CREDIBILITY IS BUILDING, STARTING WITH OUR CUSTOMERS SPINE SUMMARY: A CLEAR PATH TO IMPROVEMENT

OPPORTUNITY

Spine is a long-term global growth market that we lead today; We fully intend to strengthen our market position going forward. The Spine market is stabilizing and we are improving; focused on returning to market growth and confident we'll get there.

STABILIZATION

Making many changes including globalization, procedural innovation,

NEW STRATEGY

reverse innovation, resource reallocation and tuck-in M&A, while continuing to invest in product innovation.

VALUE


Medtronic adds unique value to Spine through integrated offerings that leverage our breadth, including Smart Surgery and Neuroscience Strategy.


21


Plus ... continuing to gain competitive advantage through our scientific, ethical, and transparent industry leadership

🕀 Medtronic


SUPERB EXECUTION, ROBUST NEW PRODUCT FLOW AND GLOBALIZATION SURGICAL TECHNOLOGIES HITTING ON ALL CYLINDERS












REVOLUTIONARY SYSTEM OFFERING INSULIN DELIVERY, CGM & THERAPY ADJUSTMENT MINIMED® 530G SYSTEM




INNOVATIVE TECHNOLOGY REMAINS OUR TOP GROWTH DRIVER INNOVATION SUMMARY: RICH TECHNOLOGY PIPELINE

	Near-Term Current-FY14	Mid-Term FY15-FY16	Long-Term FY17+
Spine	 Solera[™] 5.5/6.0, MAST[®] Deform Capstone Control[™] Bryan[®] Artificial Disc (US) 	n. • DIAM [©] (US) • Prestige LP [™] Disc (US) • Extremities Gen 2	 Sciatica Pain therapy Next-Gen BMP Carrier Post-Op Pain biologics
Neuromodulation	 RestoreSensor[®] SCS MRI Full Body for DBS InterStim[®] for Bowel 	 Next-Gen RC for SCS Brain Sensing for DBS MicroStim 	 Next-Gen Pump Next-Gen Brain Sensing for DBS CNS Drug Therapy
Diabetes	 MM 530G (US) MM 640G (EU) Sentrino[™] Hospital CGM (EU) 	 MM 640G (US) Next-Gen Enlite™ Patch Pump 	 Optical Sensor Closed Loop Overnight Fingerstick Replacement
Surgical Technologies	 MicroSaws/High Torque Power Next-Gen EMG Tube (US/EU) PowerEase[®] 	 Next Gen O-arm[®] NIM/NAV integration AE Spine/Ortho/Neuro 	 Next Gen Strata[®] Minimally Invasive Spine tools
Medtronic			



LEVERAGING OUR BREADTH WITH INTEGRATED SOLUTIONS THAT DRIVE VALUE SMART SURGERY PROCEDURAL INNOVATION



BREAKTHROUGH SOLUTION IN SPINE SURGERY THROUGH NAVIGATION TECHNOLOGY SMART SURGERY: NAVIGATED DLIF



- Industry's only 3D image-guided interbody fusion procedure
- Safer and more accurate construct placement with reduced radiation
- Fully-navigated spine surgeries reduce revision costs by 70%
- Very enthusiastic surgeon response

31

IMPROVING SPINE SURGERY THROUGH NIM, NAVIGATION AND POWER SMART SURGERY: POWEREASE®




A Medtronic

- First integration of power technology, nerve sensing and advanced imaging in the spine surgeon's hands
- Reduces time and repetitive motion/fatigue, yet increases confidence: 95% reduction in work, 55% less time and 40% greater control placing screws.

• Compatible with Solera[™] and TSRH[®] 3DX.

LEVERAGING MEDTRONIC'S UNIQUE NEURO-RELATED TECHNOLOGY AND CHANNEL BREADTH NEUROSCIENCE STRATEGY





- Medtronic leading with distinctive products, procedures, research, etc.
- Advancing the science, building our brand, and driving additional revenue

"No company has done more to advance the science and practice of neurosurgery than Medtronic... I look forward to this collaboration"

- Prominent Neurosurgery Society Leader, 2012

🕀 Medtronic





NEUROSCIENCES

33

Leveraging therapies, channels and expertise to pioneer the pain care continuum MEDTRONIC PAIN SOLUTIONS

Getting the Right Patient to the Right Physician at the Right Time for the Right Therapy **ONSET OF PAIN** CONSERVATIVE STEROID INTER-PAIN PUMPS **FUSION** PAIN STIM POST-OP. CARE VENTIONAL TREATMENT INJECTIONS **Engage patients & Develop** patient **Medtronic Therapy** physicians over pain referral networks management lifetime Multi-Specialty Scope: PM&R, Neurologist, Anesthesiologist, Neurosurgeon, Orthopedic Surgeon Clinical Pathway · Technology · Clinical Support · Post-Op. Service 🕀 Medtronic 35



TRANSFORMING OUR BUSINESSES TO WIN IN A CHANGING ENVIRONMENT RTG: STRONG ALIGNMENT WITH MEDTRONIC VISION



RTG WILL BE A SIGNIFICANT CONTRIBUTOR TO IMPROVING MEDTRONIC GROWTH RTG WELL POSITIONED IN GROWTH MARKETS



🕀 Medtronic



2012 Investor Conference

June 1, 2012 · New York City